According to a recent LinkedIn post from Acclaro Medical, the company is actively showcasing its UltraClear and AuraLux laser platforms at the AmSpa 2026 American Med Spa Association event. The post highlights live demonstrations at Booth 402 and positions these products as part of what it calls a “2910 nm Fiber Laser Revolution” for aesthetic skin treatments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post describes UltraClear as its flagship resurfacing laser, emphasizing comfort, faster healing and suitability across all skin types. AuraLux is presented as a cold fiber laser aimed at medical spas that focus on fast return on investment, strong patient demand and recurring revenue streams.
For investors, the emphasis on med spa economics and repeatable revenue suggests Acclaro Medical is targeting high-utilization, cash-pay environments that can support premium device pricing. If market adoption matches the tone of the post, stronger demand from med spa operators could support recurring consumables usage, procedure volumes and potential aftermarket service revenue.
Participation in a dedicated med spa conference may also indicate a strategic push to deepen penetration in the fast-growing aesthetic and wellness segment. While the post is promotional in nature, sustained visibility at industry events like AmSpa could help build brand recognition for UltraClear and AuraLux and potentially enhance the company’s competitive position versus other aesthetic laser manufacturers.